Products

Insider Intelligence delivers leading-edge research to clients in a variety of forms, including full-length reports and data visualizations to equip you with actionable takeaways for better business decisions.
Reports
In-depth analysis, benchmarks and shorter spotlights on digital trends.
Learn More
Forecasts
Interactive projections with 10k+ metrics on market trends, & consumer behavior.
Learn More
Charts
Proprietary data and over 3,000 third-party sources about the most important topics.
Learn More
Industry KPIs
Industry benchmarks for the most important KPIs in digital marketing, advertising, retail and ecommerce.
Learn More
Briefings
Client-only email newsletters with analysis and takeaways from the daily news.
Learn More
Analyst Access Program
Exclusive time with the thought leaders who craft our research.
Learn More

About Insider Intelligence

Our goal at Insider Intelligence is to unlock digital opportunities for our clients with the world’s most trusted forecasts, analysis, and benchmarks. Spanning five core coverage areas and dozens of industries, our research on digital transformation is exhaustive.
Our Story
Learn more about our mission and how Insider Intelligence came to be.
Learn More
Methodology
Rigorous proprietary data vetting strips biases and produces superior insights.
Learn More
Our People
Take a look into our corporate culture and view our open roles.
Join the Team
Contact Us
Speak to a member of our team to learn more about Insider Intelligence.
Contact Us
Newsroom
See our latest press releases, news articles or download our press kit.
Learn More
Advertising & Sponsorship Opportunities
Reach an engaged audience of decision-makers.
Learn More
Events
Browse our upcoming and past events, recent podcasts, and other featured resources.
Learn More
Podcasts
Tune in to eMarketer's daily, weekly, and monthly podcasts.
Learn More

Unexpected medical bills plague US consumers—here are 2 key reasons why this could improve soon

The data: 20% of adults or their families got slapped with a surprise medical bill this year, and 22% were charged over $1,000 unexpectedly, according to a June Morning Consult survey of 2,210 US adults.

Digging deeper into the data: Many US adults aren’t aware of new legislation that protects them from unanticipated billing.

  • The No Surprises Act went into effect in January to reduce the number of unanticipated out-of-network medical bills during emergency care.
  • Yet, only 16% of US adult consumers say they’ve heard, read, or seen content about the No Surprises Act, per Morning Consult.

US patients aren’t relying on insurers for deals: They’re taking matters into their own hands and tapping low-cost pharmacies or tools like Mark Cuban’s pharmacy, GoodRx, and Blink Health.

  • For example, during its Q1 call, GoodRx claimed its prescription transactions revenues increased 16% year over year, with an average of over 6.4 million monthly active consumers.

These digital-first companies are becoming more reliable for consumers, whether they’re insured or uninsured. That’s because having insurance doesn’t guarantee immunity from surprise medical billing.

  • 21% of insured adults say they received a surprise bill this year, while only 17% of uninsured patients said the same, per Morning Consult.

2 things will ease billing woes: But they'll take considerable time to implement.

1. Price transparency rules

Although hospitals are lagging on posting CMS-mandated prices for their procedures, it appears insurers are ahead of the game. Payers like United Healthcare and Anthem have already posted their rates online. It’s too early to tell whether or not it’ll reduce surprise billing for the long haul, but it could give consumers more clarity on insurance rates for certain procedures before getting treatment.

2. State-led initiatives

California recently announced it’s taking the plunge to develop its own low-cost insulin as consumer healthcare spending skyrockets.

  • California will allocate $100 million of the state budget to manufacture affordable meds, per Governor Newsom. Half of the funding will go toward building a state-based manufacturing facility, and the other half will cover the cost of producing insulin products.
  • It will likely take a while to roll out to Californians—but if successful, it could become a blueprint for other states to take a similar strategy.